Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen.

Barone A, Chi DC, Theoret MR, Chen H, He K, Kufrin D, Helms WS, Subramaniam S, Zhao H, Patel A, Goldberg KB, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Dec 15;23(24):7448-7453. doi: 10.1158/1078-0432.CCR-17-0898. Epub 2017 Aug 3.

PMID:
28774898
2.

FDA Approval Summary: Accelerated Approval of Pembrolizumab for Second-Line Treatment of Metastatic Melanoma.

Chuk MK, Chang JT, Theoret MR, Sampene E, He K, Weis SL, Helms WS, Jin R, Li H, Yu J, Zhao H, Zhao L, Paciga M, Schmiel D, Rawat R, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Oct 1;23(19):5666-5670. doi: 10.1158/1078-0432.CCR-16-0663. Epub 2017 Feb 24.

PMID:
28235882
3.

FDA Approval Summary: TAS-102.

Marcus L, Lemery SJ, Khasar S, Wearne E, Helms WS, Yuan W, He K, Cao X, Yu J, Zhao H, Wang Y, Stephens O, Englund E, Agarwal R, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Jun 15;23(12):2924-2927. doi: 10.1158/1078-0432.CCR-16-2157. Epub 2017 Feb 17.

4.

U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab.

Hazarika M, Chuk MK, Theoret MR, Mushti S, He K, Weis SL, Putman AH, Helms WS, Cao X, Li H, Zhao H, Zhao L, Welch J, Graham L, Libeg M, Sridhara R, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Jul 15;23(14):3484-3488. doi: 10.1158/1078-0432.CCR-16-0712. Epub 2017 Jan 13.

5.

FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma.

Casey D, Demko S, Shord S, Zhao H, Chen H, He K, Putman A, Helms W, Keegan P, Pazdur R.

Clin Cancer Res. 2017 May 15;23(10):2377-2381. doi: 10.1158/1078-0432.CCR-16-2051. Epub 2017 Jan 10.

6.

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.

Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G, Stephens O, Zahalka E, Ringgold K, Helms W, Shord S, Yu J, Zhao H, Davis G, McKee AE, Keegan P, Pazdur R.

Clin Cancer Res. 2016 Nov 1;22(21):5171-5176. Epub 2016 Jul 13.

7.

Cytokine release: A workshop proceedings on the state-of-the-science, current challenges and future directions.

Grimaldi C, Finco D, Fort MM, Gliddon D, Harper K, Helms WS, Mitchell JA, O'Lone R, Parish ST, Piche MS, Reed DM, Reichmann G, Ryan PC, Stebbings R, Walker M.

Cytokine. 2016 Sep;85:101-8. doi: 10.1016/j.cyto.2016.06.006. Epub 2016 Jun 13. Review.

8.

FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.

Nair A, Lemery SJ, Yang J, Marathe A, Zhao L, Zhao H, Jiang X, He K, Ladouceur G, Mitra AK, Zhou L, Fox E, Aungst S, Helms W, Keegan P, Pazdur R.

Clin Cancer Res. 2015 Dec 1;21(23):5205-8. doi: 10.1158/1078-0432.CCR-15-1377. Epub 2015 Aug 31.

9.

FDA Approval Summary: Ramucirumab for Gastric Cancer.

Casak SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, Jin R, Li H, Zhao L, Zhao H, Zhang H, Chen H, He K, Dougherty M, Novak R, Kennett S, Khasar S, Helms W, Keegan P, Pazdur R.

Clin Cancer Res. 2015 Aug 1;21(15):3372-6. doi: 10.1158/1078-0432.CCR-15-0600. Epub 2015 Jun 5.

10.

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, Fox E, Helms W, Leong R, Song P, Pan Y, Liu Q, Zhao P, Zhao H, Lu D, Tang Z, Al Hakim A, Boyd K, Keegan P, Justice R, Pazdur R.

Clin Cancer Res. 2015 Jun 1;21(11):2436-9. doi: 10.1158/1078-0432.CCR-14-3157. Epub 2015 Mar 9.

11.

FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.

Kim G, McKee AE, Ning YM, Hazarika M, Theoret M, Johnson JR, Xu QC, Tang S, Sridhara R, Jiang X, He K, Roscoe D, McGuinn WD, Helms WS, Russell AM, Miksinski SP, Zirkelbach JF, Earp J, Liu Q, Ibrahim A, Justice R, Pazdur R.

Clin Cancer Res. 2014 Oct 1;20(19):4994-5000. doi: 10.1158/1078-0432.CCR-14-0776. Epub 2014 Aug 5. Review.

12.

U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.

Malik SM, Maher VE, Bijwaard KE, Becker RL, Zhang L, Tang SW, Song P, Liu Q, Marathe A, Gehrke B, Helms W, Hanner D, Justice R, Pazdur R.

Clin Cancer Res. 2014 Apr 15;20(8):2029-34. doi: 10.1158/1078-0432.CCR-13-3077. Epub 2014 Feb 26.

13.

Regulation of immunotherapeutic products for cancer and FDA's role in product development and clinical evaluation.

Vatsan RS, Bross PF, Liu K, Theoret M, De Claro AR, Lu J, Helms W, Niland B, Husain SR, Puri RK.

J Immunother Cancer. 2013 May 29;1:5. doi: 10.1186/2051-1426-1-5. eCollection 2013. Review.

14.

Roundtable on expanding capacity for comparative effectiveness research in the United States: discussion took place on June 3, 2007, at the AcademyHealth Annual Research Meetingin Orlando, FL.

Tunis S, Clancy C, Helms WD, McGinnis JM, Pearson SD.

Health Serv Res. 2009 Apr;44(2 Pt 1):327-42. doi: 10.1111/j.1475-6773.2009.00947.x. Epub 2009 Feb 4. No abstract available.

15.

Contrasting roles for all-trans retinoic acid in TGF-beta-mediated induction of Foxp3 and Il10 genes in developing regulatory T cells.

Maynard CL, Hatton RD, Helms WS, Oliver JR, Stephensen CB, Weaver CT.

J Exp Med. 2009 Feb 16;206(2):343-57. doi: 10.1084/jem.20080950. Epub 2009 Feb 9.

16.

Modulation of NFAT-dependent gene expression by the RhoA signaling pathway in T cells.

Helms WS, Jeffrey JL, Holmes DA, Townsend MB, Clipstone NA, Su L.

J Leukoc Biol. 2007 Aug;82(2):361-9. Epub 2007 May 14.

17.

Transforming growth factor-beta induces development of the T(H)17 lineage.

Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT.

Nature. 2006 May 11;441(7090):231-4. Epub 2006 Apr 30.

PMID:
16648837
18.
19.

Galpha13 mediates a signal that is essential for proliferation and survival of thymocyte progenitors.

Coffield VM, Helms WS, Jiang Q, Su L.

J Exp Med. 2004 Nov 15;200(10):1315-24. Epub 2004 Nov 8.

20.

Real-time quantitative analysis of H2, He, O2, and Ar by quadrupole ion trap mass spectrometry.

Ottens AK, Harrison WW, Griffin TP, Helms WR.

J Am Soc Mass Spectrom. 2002 Sep;13(9):1120-8.

PMID:
12322959
21.

Evaluation of small mass spectrometer systems for permanent gas analysis.

Arkin CR, Griffin TP, Ottens AK, Diaz JA, Follistein DW, Adams FW, Helms WR.

J Am Soc Mass Spectrom. 2002 Aug;13(8):1004-12.

PMID:
12216728
22.

RhoA biological activity is dependent on prenylation but independent of specific isoprenoid modification.

Solski PA, Helms W, Keely PJ, Su L, Der CJ.

Cell Growth Differ. 2002 Aug;13(8):363-73.

23.

State coverage expansions: learning from research and practice.

Gauthier AK, Gates VS, Helms WD.

Health Serv Res. 2002 Feb;37(1):33-42. No abstract available.

PMID:
11949924
24.

Identification of chromosomal deficiencies that modify Drosophila mastermind mutant phenotypes.

Yedvobnick B, Helms W, Barrett B.

Genesis. 2001 Aug;30(4):250-8.

PMID:
11536431
25.

1Q[3a]. Allow individuals to buy into the federal health plan?

Moffit RE, Hinchey M, Helms WD.

Hosp Health Netw. 2001 Jun;75(6):32. No abstract available.

PMID:
11432286
26.

Engineered truncations in the Drosophila mastermind protein disrupt Notch pathway function.

Helms W, Lee H, Ammerman M, Parks AL, Muskavitch MA, Yedvobnick B.

Dev Biol. 1999 Nov 15;215(2):358-74.

27.

Use of heme-protein complexes by the Yersinia enterocolitica HemR receptor: histidine residues are essential for receptor function.

Bracken CS, Baer MT, Abdur-Rashid A, Helms W, Stojiljkovic I.

J Bacteriol. 1999 Oct;181(19):6063-72.

28.

Natural selection and high heels.

Smith EO, Helms WS.

Foot Ankle Int. 1999 Jan;20(1):55-7. No abstract available.

PMID:
9921776
29.

State trends in hospital uncompensated care.

Atkinson G, Helms WD, Needleman J.

Health Aff (Millwood). 1997 Jul-Aug;16(4):233-41.

PMID:
9248169
30.

State models: an overview. Tracking states' efforts to reform their health systems.

Rogal DL, Helms WD.

Health Aff (Millwood). 1993 Summer;12(2):27-30. No abstract available.

PMID:
8375820
31.

Health care reform in rural areas.

Campion DM, Helms WD, Barrand NL.

Health Aff (Millwood). 1993 Fall;12(3):76-80. No abstract available.

PMID:
8244249
32.

Mending the flaws in the small-group market.

Helms WD, Gauthier AK, Campion DM.

Health Aff (Millwood). 1992 Summer;11(2):7-27. No abstract available.

PMID:
1500061
33.

Policy and practice: certified home health care in New York City.

Fox KS, Helms WD, Ginsburg S.

Pap Ser United Hosp Fund N Y. 1990 Aug;(11):1-46. No abstract available.

PMID:
10126101
34.

New initiatives to expand health insurance.

Helms WD, DeSonia R.

Bus Health. 1988 Dec;6(2):12-4. No abstract available.

PMID:
10291166
35.

Bluetongue in free-ranging pronghorn antelope (Antilocapra americana) in Wyoming: 1976 and 1984.

Thorne ET, Williams ES, Spraker TR, Helms W, Segerstrom T.

J Wildl Dis. 1988 Jan;24(1):113-9.

PMID:
2832621
36.

Health planning and regulation in transition: a status report on local and state activities.

Helms WD.

Psychiatr Hosp. 1982 Summer;13(3):109-11. No abstract available.

PMID:
10258863
37.

[Nitrogen and amino acid content in sow's milk at different stages of lactation].

Helms W, Mohme H.

Z Tierphysiol Tierernahr Futtermittelkd. 1977 Mar;38(3):131-7. German. No abstract available.

PMID:
16414
38.

Leukorrhea.

HELMS WC.

J Med Assoc Ga. 1953 Aug;42(8):376-81. No abstract available.

PMID:
13085113

Supplemental Content

Support Center